Columbia University Medical Center

Alfred Neugut Comments in JAMA on Aspirin as Adjuvant Therapy for Stage 3 Colon Cancer

76800137In a commentary published online in JAMA on March 31, 2014, Alfred I. Neugut, MD, PhD, the Myron M. Studner Professor of Cancer Research and professor of epidemiology, concludes that, “if one just simplistically does a back-of-the-envelope risk-benefit analysis of aspirin use vs chemotherapy, one must begin to wonder whether it is not time to make aspirin a part of the conventional standard of care for this disease, given the relatively low risk profile of aspirin.” He writes that so far he has not recommended aspirin for colon cancer—but given recent findings, if he himself had a stage 3 tumor, he would add it to his adjuvant therapy. “And if I feel that way for myself, should I not convey that to my patients?”

Also on CUMC News: